Vertex Pharmaceuticals and NHS England Reach Agreement to Provide Alyftrek for Cystic Fibrosis Treatment

Vertex Pharmaceuticals and NHS England have finalized a reimbursement agreement for Alyftrek, a medication designed to treat cystic fibrosis (CF). The announcement confirms that patients in England will now have access to the drug under the terms of this arrangement.

Alyftrek is one of Vertex’s treatments aimed at addressing CF, a genetic disorder that affects the lungs and digestive system. The agreement marks an important step in ensuring availability of the medicine through NHS England. Details regarding the financial terms or specific provisions of the reimbursement deal were not disclosed in the announcement.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: July 15, 2025

Author

Mark Chiang